Comments on: Dendreon Tames Short Sellers, Transforms Itself into Old-School Buy-and-Hold Stock http://www.xconomy.com/seattle/2009/06/30/dendreon-tames-short-sellers-transforms-itself-into-old-school-buy-and-hold-stock/ Business + Technology in the Exponential Economy Sat, 21 Nov 2009 17:25:59 -0600 http://wordpress.org/?v=2.8.6 hourly 1 By: Luke Timmerman http://www.xconomy.com/seattle/2009/06/30/dendreon-tames-short-sellers-transforms-itself-into-old-school-buy-and-hold-stock/comment-page-1/#comment-67921 Luke Timmerman Wed, 01 Jul 2009 04:07:44 +0000 http://www.xconomy.com/?p=31271#comment-67921 Steve, you make a very astute comment about stumbles that Immunex and Icos made that led them to end up getting acquired rather than remaining independent. Dendreon is in a rare position as a biotech to still be holding onto 100 percent ownership of a drug with $1 billion U.S. sales potential, that has passed Phase III clinical trials. Steve, you make a very astute comment about stumbles that Immunex and Icos made that led them to end up getting acquired rather than remaining independent. Dendreon is in a rare position as a biotech to still be holding onto 100 percent ownership of a drug with $1 billion U.S. sales potential, that has passed Phase III clinical trials.

]]> By: Fast Money – Dendreon Tames Short Sellers, Transforms Itself into Old-School Buy – Xconomy « Fast Money http://www.xconomy.com/seattle/2009/06/30/dendreon-tames-short-sellers-transforms-itself-into-old-school-buy-and-hold-stock/comment-page-1/#comment-67910 Fast Money – Dendreon Tames Short Sellers, Transforms Itself into Old-School Buy – Xconomy « Fast Money Wed, 01 Jul 2009 00:46:52 +0000 http://www.xconomy.com/?p=31271#comment-67910 [...] Dendreon Tames Short Sellers, Transforms Itself into Old-School Buy – XconomyDendreon has had enough of the fast money world. The short sellers who hope to profit from a falling stock, and the hedge fund players who thrive on volatility that comes from rumors and speculation, turned this Seattle-based biotech company into one [...] [...] Dendreon Tames Short Sellers, Transforms Itself into Old-School Buy – XconomyDendreon has had enough of the fast money world. The short sellers who hope to profit from a falling stock, and the hedge fund players who thrive on volatility that comes from rumors and speculation, turned this Seattle-based biotech company into one [...]

]]> By: Steven http://www.xconomy.com/seattle/2009/06/30/dendreon-tames-short-sellers-transforms-itself-into-old-school-buy-and-hold-stock/comment-page-1/#comment-67857 Steven Tue, 30 Jun 2009 14:33:36 +0000 http://www.xconomy.com/?p=31271#comment-67857 From Schiffman's quote... “We have the potential to become a large biotech company. We have 100 percent ownership of our lead product candidate, and we have a platform behind that with many more opportunities,” Schiffman says. “I don’t think we ever should have had the drama that we had the past two years.” Luke, Again thanks for the even handed reporting. Just the facts is all I want and I got them in this article. So tired of the rif raf....! Amgen partnered Epogen world wide including the U.S. and didn't know what they had until the cancer application was discovered. They fought with J&J for years in court. ICOS partnered world wide and IMHO gave up the store to LLY who eventually bought ICOS for a song and left an empty parking lot in Bothel where once a good company stood. Imunex had a blockbuster,Embrel, for rheumatoid arthritus that they couldn't produce in quantity...and therefore could not remain independant. Dendreon may have learned from the mistakes of the past. They wish to own all the rights to Provenge in this country and they will be able to manufacture all the Provenge they will need. Some interesting possibilities for little Dendreon, that company that never gave up when many others might have. Thanks again...Steven From Schiffman’s quote…

“We have the potential to become a large biotech company. We have 100 percent ownership of our lead product candidate, and we have a platform behind that with many more opportunities,” Schiffman says. “I don’t think we ever should have had the drama that we had the past two years.”

Luke, Again thanks for the even handed reporting. Just the facts is all I want and I got them in this article.

So tired of the rif raf….!

Amgen partnered Epogen world wide including the U.S. and didn’t know what they had until the cancer application was discovered. They fought with J&J for years in court.

ICOS partnered world wide and IMHO gave up the store to LLY who eventually bought ICOS for a song and left an empty parking lot in Bothel where once a good company stood.

Imunex had a blockbuster,Embrel, for rheumatoid arthritus that they couldn’t produce in quantity…and therefore could not remain independant.

Dendreon may have learned from the mistakes of the past. They wish to own all the rights to Provenge in this country and they will be able to manufacture all the Provenge they will need.

Some interesting possibilities for little Dendreon, that company that never gave up when many others might have.

Thanks again…Steven

]]>